• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    QT Imaging Holdings Announces Partnership with Premier Cancer Center, The Vincere Cancer Center in Scottsdale, AZ

    5/8/24 8:30:00 AM ET
    $QTI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $QTI alert in real time by email

    QT Imaging Holdings, Inc. (NASDAQ:QTI) ("QT Imaging") a medical device company engaged in research, development, and commercialization of innovative body imaging systems, together with its strategic business and distribution partner, is proud to announce its partnership with The Vincere Cancer Center in Scottsdale, AZ.

    The Vincere Cancer Center is a top cancer center in the U.S. Founded by Dr. Vershalee Shukla and Dr. Pablo Prichard, the Center focuses on cancer prevention, early detection, and specializes in radiation therapy, surgery, and chemotherapy. Using innovative precision technology, the Center is renowned for its comprehensive cancer services. Dr. Prichard and Dr. Shukla, a board-certified reconstructive surgeon and radiation oncologist, built their practice to deliver superior cancer care to a variety of patients. They employ innovative technology to mitigate against over-diagnoses while ensuring cancer is not missed. Dr. Shukla, a long-standing supporter of QT Imaging and its technology, applies the QT Imaging Breast Acoustic CT™ Scanner in their breast screening environment.

    "In recent years, there has been an increased rate of breast cancer incidents, especially amongst women younger than 40, the recommended age of initial mammogram screening," said Dr. Shukla, Director of The Vincere Cancer Center. "Despite this, there has been very little technological advancement in detection of breast cancer that is suitable and accessible to all women. By harnessing the power of the QT Imaging Breast Acoustic CT™ Scanner and eliminating the discomfort associated with traditional methods, our partnership with QT Imaging is redefining standards of care and empowering patients with precision and safety."

    "The QT Imaging team's mission is to expand access to medical imaging while ensuring superior patient experience, lowering costs for providers, and improving health outcomes," said Dr. Raluca Dinu, Chief Executive Officer. "We are incredibly excited about the opportunity to work with such a prestigious cancer center and to be able to provide women a choice in their care that is safe and doesn't jeopardize accuracy or accessibility. The partnership with Vincere Cancer Center represents the continuation of our swift commercialization plan since the company went public two months ago."

    About QT Holding, Inc.

    QT Imaging Holdings, Inc. is a public (NASDAQ:QTI) medical device company engaged in research, development, and commercialization of innovative body imaging systems using low frequency sound waves. QT Imaging strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient's experience. For more information on QT Imaging, please visit the company's website at www.qtimaging.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as "will," and "expect," or the negative thereof or comparable terminology, and include (without limitation) statements regarding the partnership between QT Imaging and The Vincere Cancer Center, the QT Imaging Breast Acoustic CTTM Scanner, plans for QT Imaging, new product development and introduction, and product sales growth and projected revenues. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These risks include, but are not limited to: the ability of the parties to sell and deploy the QT Imaging Breast Acoustic CTTM Scanner, the ability to extend product offerings into new areas or products, the ability to commercialize technology, unexpected occurrences that deter the full documentation and "bring to market" plan for products, trends and fluctuations in the industry, changes in demand and purchasing volume of customers, unpredictability of suppliers, the ability to attract and retain qualified personnel and the ability to move product sales to production levels. Additional factors that could cause actual results to differ are discussed under the heading "Risk Factors" and in other sections of QT Imaging's (and its predecessor, GigCapital5, Inc.) filings with the SEC, and in its other current and periodic reports filed or furnished from time to time with the SEC. All forward-looking statements in this press release are made as of the date hereof, based on information available to QT Imaging as of the date hereof, and QT Imaging assumes no obligation to update any forward-looking statement.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240508165692/en/

    Get the next $QTI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QTI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $QTI
    SEC Filings

    View All

    SEC Form EFFECT filed by QT Imaging Holdings Inc.

    EFFECT - QT IMAGING HOLDINGS, INC. (0001844505) (Filer)

    4/6/26 12:15:18 AM ET
    $QTI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form EFFECT filed by QT Imaging Holdings Inc.

    EFFECT - QT IMAGING HOLDINGS, INC. (0001844505) (Filer)

    4/1/26 12:15:22 AM ET
    $QTI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form EFFECT filed by QT Imaging Holdings Inc.

    EFFECT - QT IMAGING HOLDINGS, INC. (0001844505) (Filer)

    4/1/26 12:15:13 AM ET
    $QTI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $QTI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    QT Imaging Debuts the QT Imaging-Olea Viewer for Integrated, Multimodality Breast Imaging Within a Single User Interface

    New Viewer, Optimized for QT Imaging's Breast Imaging Technology, Simplifies Correlation of Breast Imaging Across Modalities and Over Time, and Supports Future Integration of AI/ML-Based Tools Product Demonstrations Available at the SBI Breast Imaging Symposium, April 16-19 in Seattle QT Imaging Holdings, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company"), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today announced the launch of the QTI Imaging-Olea Viewer, developed in collaboration with Olea Medical, a leader in advanced imaging software solutions. The QT Imaging-Olea Viewer provides a unified plat

    4/15/26 8:30:00 AM ET
    $QTI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    QT Imaging Releases Its Next Generation Breast Imaging Reconstruction Software

    – New generation reconstruction software improves image quality and performance across challenging breast imaging cases – QT Imaging Holdings, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company"), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today announced its latest image reconstruction software update release, version 4.5.0. This next-generation software improves spatial resolution in reflection imaging by implementing optimized, spatially varying deconvolution during reflection image reconstruction, resulting in more accurate image representation while maintaining efficient processing times. Version 4

    4/1/26 8:30:00 AM ET
    $QTI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    QT Imaging Reports 2025 Fourth Quarter and Full Year Financial Results

    2025 Revenue of $18.9 Million Exceeded Outlook with a Record 40 Scanners Shipped Affirms 2026 Revenue Guidance of $39 Million from Contracted Scanner MOQs and Initial QTI Cloud Platform Revenue Advances Transition to a SaaS- and Biomarker-Driven Medical Imaging Platform Conference Call Begins Today at 4:30 p.m. Eastern Time QT Imaging Holdings, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company"), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today reported financial results for the three and twelve months ended December 31, 2025 and provided a business update. "I am proud of the transformation QT Im

    3/25/26 8:00:00 AM ET
    $QTI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $QTI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Greene James S bought $250,000 worth of shares (428,082 units at $0.58) (SEC Form 4)

    4 - QT IMAGING HOLDINGS, INC. (0001844505) (Issuer)

    11/14/24 9:04:44 PM ET
    $QTI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Dickson Daniel H bought $50,000 worth of shares (85,616 units at $0.58) (SEC Form 4)

    4 - QT IMAGING HOLDINGS, INC. (0001844505) (Issuer)

    11/14/24 9:03:54 PM ET
    $QTI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chairman Katz Avi S bought $1,834,999 worth of shares (3,142,122 units at $0.58), increasing direct ownership by 252% to 657,960 units (SEC Form 4)

    4 - QT IMAGING HOLDINGS, INC. (0001844505) (Issuer)

    11/14/24 9:03:30 PM ET
    $QTI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $QTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Taylor Ross

    4 - QT IMAGING HOLDINGS, INC. (0001844505) (Issuer)

    3/24/26 9:44:03 PM ET
    $QTI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Weiner Zeev

    4 - QT IMAGING HOLDINGS, INC. (0001844505) (Issuer)

    3/24/26 9:42:16 PM ET
    $QTI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Greene James S

    4 - QT IMAGING HOLDINGS, INC. (0001844505) (Issuer)

    3/24/26 9:39:48 PM ET
    $QTI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $QTI
    Leadership Updates

    Live Leadership Updates

    View All

    QT Imaging Announces First Quarter 2024 Financial Results

    Generated Scanner Sales Revenue of $1.4M with 56% Gross Margin in the First Quarter of 2024, Since the Company Became Public on March 4th Streamlined Business Model via Strategic Sales and Distribution Partnership in USA Reported in Academic Radiology the Results of a Second Blinded Screening Trial That Found That QTI Technology Is Similarly Effective as Digital Breast Tomosynthesis (DBT) or 3D Mammography Company Completed Merger with GigCapital5 QT Imaging Holdings, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company"), a medical device company engaged in research, development, and commercialization of innovative body imaging systems, today announced financial results for the first qu

    5/10/24 8:57:00 AM ET
    $QTI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $QTI
    Financials

    Live finance-specific insights

    View All

    QT Imaging Reports 2025 Fourth Quarter and Full Year Financial Results

    2025 Revenue of $18.9 Million Exceeded Outlook with a Record 40 Scanners Shipped Affirms 2026 Revenue Guidance of $39 Million from Contracted Scanner MOQs and Initial QTI Cloud Platform Revenue Advances Transition to a SaaS- and Biomarker-Driven Medical Imaging Platform Conference Call Begins Today at 4:30 p.m. Eastern Time QT Imaging Holdings, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company"), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today reported financial results for the three and twelve months ended December 31, 2025 and provided a business update. "I am proud of the transformation QT Im

    3/25/26 8:00:00 AM ET
    $QTI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    QT Imaging to Hold 2025 Fourth Quarter and Full Year Conference Call on March 25, 2026

    QT Imaging Holdings, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company"), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today announced that it will report financial results for the three and 12 months ended December 31, 2025 after market close on Wednesday, March 25, 2026 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time: Wednesday, March 25, 4:30 p.m. ET / 1:30 p.m. PT   Pre-Registration: Participants can pre-register for the conference call here: Callers who pre-register will be given a conference passcode and uniqu

    3/18/26 8:30:00 AM ET
    $QTI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    QT Imaging Reports Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results

    Generated Record Revenue of $8.3 Million in Q4 2025, up 97% versus Q3 2025 Shipped Record 17 Scanners in Q4 2025 and 40 in 2025, up from 12 Scanners Shipped in 2024 Exceeded 2025 Sales Outlook, Delivering Revenue of $18.9 Million Relisted on Nasdaq Less Than One Year After Leaving the Exchange Continues to Pivot from a Scanner Company to a SaaS and Biomarker-Driven Medical Imaging Franchise QT Imaging Holdings, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company") a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today announces preliminary unaudited financial results for the fourth quarter and full year

    2/18/26 8:30:00 AM ET
    $QTI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $QTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by QT Imaging Holdings Inc.

    SC 13D/A - QT IMAGING HOLDINGS, INC. (0001844505) (Subject)

    11/22/24 4:15:11 PM ET
    $QTI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by QT Imaging Holdings Inc.

    SC 13G - QT IMAGING HOLDINGS, INC. (0001844505) (Subject)

    11/14/24 4:01:08 PM ET
    $QTI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13D/A filed by QT Imaging Holdings Inc.

    SC 13D/A - QT IMAGING HOLDINGS, INC. (0001844505) (Subject)

    9/13/24 4:23:43 PM ET
    $QTI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care